Business Wire

Lineage Opens Latest Fully-Automated Cold-Storage Warehouse Expansion in Peterborough to Create South East Superhub

19.5.2022 09:00:00 EEST | Business Wire | Press release

Share

Lineage Logistics, LLC (“Lineage” or the “Company”), one of the world’s leading temperature-controlled industrial REIT and logistics solutions providers, today unveiled its South East Superhub in Peterborough, Cambridgeshire, just 70 miles from Central London and 120 miles from its Northern Superhub in Heywood near Manchester.

Lineage completed the new, fully-automated warehouse expansion with an additional 45,000 pallet positions in Peterborough, bringing the total capacity to nearly 71,000 pallets today. The expanded warehouse creates a strategically-positioned South East Superhub, which will serve both retail and foodservice customers with unique supply chain requirements. This 35-metre tall expansion will feature some of the world’s most sophisticated automation and refrigeration technology, helping to reduce energy consumption and the environmental impact of food distribution.

“We are investing in the future of food supply chain across Europe, using the latest technology, data analytics and green solutions to help feed the world in the most efficient way possible. Our Peterborough Superhub is the latest demonstration of Lineage’s ongoing commitment to our UK customers and an indication of our aim to be a leader in this crucial sector across Europe,” said Harld Peters, President of Europe at Lineage.

Lineage is committed to achieving net zero greenhouse gas emissions, and achieving this goal goes hand in hand with innovation, which is why the South East Superhub has the latest data-driven solutions to optimize energy use, with precision cooling cycles and full automation to minimize energy leakage.

The combination of traditional capacity in Lineage’s existing facilities on the site, combined with the expansion’s automated design, will enable maximum flexibility and a highly-customized solution for customers. This investment brings Lineage’s total automated warehouse count in the UK to six, with a total of 335,000 automated pallet positions.

The South East Superhub launch follows the expansion of Lineage’s Northern Superhub near Manchester, in September 2021, which added 22,000 pallet positions in a state-of-the-art facility. Together, these warehouses serve the main population and economic centres in England, and complement Lineage’s other facilities in the UK, ensuring that food service and retail customers across the country have access to reliable, sustainable and efficient warehouses to store cold and frozen food on the way to the final customer.

“At a time of supply chain volatility, Lineage’s Peterborough Superhub will play a key role in ensuring a reliable food supply in the most densely populated part of the UK,” said Tim Moran, Lineage’s Senior Vice President for Operations in Europe. “Additionally, we’ll be able to meet growing customer demand from both online and conventional grocery sales, an accelerated trend coming out of the COVID-19 pandemic as well as the disruption of supplies stemming from Russia’s invasion of Ukraine.”

Lineage Logistics is one of the largest temperature-controlled logistics providers in the UK. At the same time, Lineage has been expanding its network across Europe in recent years, creating a one-stop-shop solution for customers across the continent. This reduces the complexity of moving food between countries, reduces food waste and makes the distribution of food and goods requiring cold storage more efficient.

“Our large expansions in these two critical logistics hubs highlight Lineage’s commitment to adapting to our customers’ demands as consumer expectations shift in the UK and around the globe,” said Greg Lehmkuhl, President and Chief Executive Officer of Lineage. “We are, and have always been, 100% focused on our customers and their extended supply chains, and we are pleased to make these significant investments, create more than 230 much-needed jobs and provide expanded access to our next-generation cold storage network.”

About Lineage Logistics

Lineage Logistics is one of the world’s leading temperature-controlled industrial REIT and logistics solutions providers. It has a global network of over 400 strategically located facilities totaling over 2 billion cubic feet of capacity, which spans 20 countries across North America, Europe, and Asia-Pacific. Lineage’s industry-leading expertise in end-to-end logistical solutions, its unrivaled real estate network and the development and deployment of innovative technology help increase distribution efficiency, advance sustainability, minimize supply chain waste, and, most importantly, as a Visionary Partner of Feeding America, help feed the world. In recognition of the company’s leading innovations and sustainability initiatives, Lineage was a 2022 U.S. Best Managed Company, No. 3 in the 2022 CNBC Disruptor 50 list, No. 17 in the 2021 CNBC Disruptor 50 list, the No 1. Data Science company, and 23rd overall, on Fast Company’s 2019 list of The World’s Most Innovative Companies, in addition to being included on Fortune’s Change The World list in 2020. (www.lineagelogistics.com)

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contacts:
Lineage Logistics
Magnus Franklin
+32471620575
magnus.franklin@teneo.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye